Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies

The World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such heavy pill regimen, prolonged treatment duration, and strict schedule, to multidrug-resistant (MDR) extensively drug-resistant (XDR) strains. rise of MDR strains endangers future control. Despite these concerns, the hunt an efficient continues. One breakthrough has been use nanotechnology in medicines, presenting novel approach treatment. Nanocarriers, lipid nanoparticles, nanosuspensions, liposomes, polymeric micelles, facilitate targeted delivery anti-TB drugs. benefits nanocarriers include reduced drug doses, fewer side effects, improved solubility, better bioavailability, patient compliance, speeding up recovery. Additionally, can be made even more linking them ligands mannose or hyaluronic acid. This review explores innovative treatments, including studies on containing drugs related patents.